Hereditary Diffuse Gastric Cancer (CDH1 mutation)

1. Executive Overview: Understanding CDH1-Related Gastric Cancer

Hereditary Diffuse Gastric Cancer (HDGC) is a rare, autosomal dominant cancer predisposition syndrome characterized by a significantly elevated lifetime risk of developing diffuse-type gastric cancer. At the molecular level, this condition is primarily driven by germline pathogenic variants in the CDH1 gene, which encodes for the protein E-cadherin.

Unlike intestinal-type gastric cancer, which often presents as a distinct mass, diffuse gastric cancer (also known as linitis plastica) infiltrates the stomach wall, making it notoriously difficult to detect via standard endoscopic surveillance. Because the cancer develops beneath the mucosal surface, early-stage lesions are often missed during routine gastroscopy. Consequently, the clinical management of CDH1 mutation carriers focuses heavily on prophylactic surgical intervention.

This guide provides a comprehensive overview for patients and families navigating the implications of a CDH1 mutation, adhering to the latest international clinical guidelines.

2. Pathophysiology, Etiology, and Risk Factors

The Role of E-Cadherin

The CDH1 gene provides instructions for producing E-cadherin, a transmembrane glycoprotein essential for cell-to-cell adhesion in epithelial tissues. E-cadherin acts as a tumor suppressor by maintaining the structural integrity of the gastric lining.

• Mechanism of Loss: In HDGC, a "second hit" (somatic mutation or epigenetic silencing) occurs in the remaining wild-type allele, leading to a complete loss of E-cadherin function.
• Resultant Phenotype: Without functional E-cadherin, cells lose their ability to adhere to one another. This allows malignant cells to infiltrate the gastric stroma, resulting in the "signet ring cell" morphology characteristic of diffuse gastric cancer.

Genetic Inheritance

HDGC follows an autosomal dominant inheritance pattern. This means that an individual with a pathogenic CDH1 variant has a 50% probability of passing the mutation to each offspring. It is essential to note that "incomplete penetrance" and "variable expressivity" are common, meaning not all carriers will develop cancer at the same age, or in some cases, at all.

Risk Stratification

3. Signs, Symptoms, and Clinical Presentation

Diffuse gastric cancer is frequently asymptomatic in its early stages. Because the disease is infiltrative rather than mass-forming, patients rarely present with early warning signs like hematemesis (vomiting blood) or obstruction until the disease is advanced.

Common symptoms of advanced disease include:
* Early satiety: Feeling full after eating only a small amount of food.
* Dysphagia: Difficulty swallowing.
* Unexplained weight loss: Often associated with cachexia.
* Epigastric pain: Persistent dull ache in the upper abdomen.
* Iron deficiency anemia: Resulting from chronic, occult blood loss.

4. Standard Diagnostic Evaluation & Workup

The diagnosis of CDH1-associated HDGC relies on a combination of genetic testing and rigorous endoscopic surveillance.

Genetic Testing Criteria

Testing is recommended for families meeting the International Gastric Cancer Linkage Consortium (IGCLC) criteria:
1. Two or more documented cases of gastric cancer in a family, with at least one confirmed diffuse gastric cancer at age <50.
2. Three or more cases of documented diffuse gastric cancer in first- or second-degree relatives, regardless of age.
3. Personal or family history of diffuse gastric cancer and lobular breast cancer (one diagnosed before age 50).

Diagnostic Modalities

• Genetic Assay: Next-generation sequencing (NGS) of the CDH1 gene is the gold standard for identifying pathogenic germline mutations.
• Endoscopic Surveillance: While standard white-light endoscopy is insufficient to detect early HDGC, high-definition endoscopy with chromoendoscopy (using dyes like indigo carmine) is used in centers specializing in HDGC.
• Pathology: The hallmark finding is the presence of signet ring cells within the gastric mucosa, even in the absence of a visible tumor.

5. Therapeutic Interventions and Management

Prophylactic Total Gastrectomy (PTG)

Given the high risk of occult cancer and the poor sensitivity of endoscopic screening, prophylactic total gastrectomy is the standard of care for asymptomatic CDH1 mutation carriers.
* Timing: Usually recommended between the ages of 18 and 30, depending on the youngest age of onset in the family.
* Procedure: The entire stomach is removed, and the esophagus is reconstructed to the small intestine (esophagojejunostomy).

Long-Term Post-Gastrectomy Care

Patients undergo a significant lifestyle shift post-surgery, requiring:
* Dietary Modifications: Eating 6–8 small, high-protein, low-sugar meals per day to avoid "dumping syndrome."
* Nutritional Supplementation: Mandatory lifelong monitoring and supplementation of Vitamin B12, Iron, Calcium, and Vitamin D.
* Psychosocial Support: Managing the psychological impact of living without a stomach and the anxiety associated with genetic diagnosis.

Breast Cancer Surveillance

For female carriers, the risk of lobular breast cancer is high. Surveillance includes:
* Annual breast MRI starting at age 30.
* Clinical breast exams every 6–12 months.
* Discussion of risk-reducing options, including prophylactic mastectomy.

6. Massive FAQ Section

1. If I have the CDH1 mutation, does it mean I will definitely get cancer?

No. While the risk is high (70–80%), it is not 100%. However, due to the difficulty of early detection, clinical guidelines strongly recommend prophylactic surgery.

2. Is there a blood test to detect early gastric cancer?

Currently, there is no reliable blood-based biomarker for early-stage diffuse gastric cancer. Imaging like CT scans often fails to detect early-stage intramucosal lesions.

3. Can I just do regular endoscopies instead of surgery?

Endoscopy is notoriously poor at detecting diffuse gastric cancer because the cancer spreads beneath the lining. Even with multiple biopsies, it is easy to miss microscopic pockets of cancer.

4. What is the impact on life expectancy after a total gastrectomy?

Most patients adapt well to life without a stomach. While dietary habits change permanently, patients generally return to a full, active life after a recovery period.

5. At what age should I start genetic testing?

Testing is typically offered to adults. For children of carriers, testing is often deferred until age 18, unless there is a family history of very early-onset cancer.

6. Is CDH1 mutation linked to other cancers?

Yes, it is strongly associated with lobular breast cancer in women and has been linked to an increased risk of colorectal cancer, though the latter is less common.

7. Does the CDH1 mutation affect pregnancy?

The mutation itself does not affect fertility. However, patients should discuss genetic counseling and potential preimplantation genetic testing (PGT) if they wish to avoid passing the mutation to their children.

8. What is "Linitis Plastica"?

It is a descriptive term for the appearance of the stomach in advanced diffuse gastric cancer, where the stomach wall becomes thick, rigid, and "leather-bottle" like.

9. Are there any medications to prevent this cancer?

Currently, there are no pharmacologic agents (chemoprevention) proven to prevent the development of gastric cancer in CDH1 mutation carriers.

10. How do I find a specialist for this condition?

You should seek care at a comprehensive cancer center with a dedicated Cancer Genetics Program and a high-volume surgical oncology department experienced in prophylactic gastrectomy.

Medical Disclaimer: This guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or genetic diagnosis.

Related Clinical Integration

In the comprehensive management of Hereditary Diffuse Gastric Cancer (CDH1 mutation), clinical precision is paramount, particularly when navigating the complexities of prophylactic total gastrectomy where advanced technology like the Harmonic Scalpel / مشرط هارمونيك is essential for meticulous tissue dissection and hemostasis. Beyond the immediate surgical intervention, our multidisciplinary approach emphasizes the importance of continuous professional development and diagnostic proficiency; clinicians are encouraged to refine their oncological expertise by engaging with ABOS Orthopedic Board Review: Primary Bone Tumors, Chondromas, & MSK Pathology | Part 9, Musculoskeletal Tumors: Lipomas, Osteosarcoma, HME for ABOS Board Review | Part 14, and ABOS Board Review: Orthopedic Pathology, Bone Tumors, Skeletal Dysplasias, Arthritis | Part 12. These resources ensure that our medical staff remains adept at recognizing systemic manifestations and complex pathologies that may intersect with the broader spectrum of hereditary cancer syndromes and metastatic disease, thereby fostering a holistic, evidence-based environment for patient care.